Author/Creator: Parameswaran, V. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Parameswaran, V.

1. Association between osteoarthritis-related serum biochemical markers over 11 years and knee MRI-based imaging biomarkers in middle-aged adults. Issue 5 (May 2022)

Authors:: Singh, A.; Venn, A.; Blizzard, L.; Jones, G.; Burgess, J.; Parameswaran, V.; Cicuttini, F.; March, L.; Eckstein, F.; Wirth, W.; Ding, C.; Antony, B.
Journal:: Osteoarthritis and cartilage
Issue:: Volume 30:Issue 5(2022)
Page Start:: 756
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Association between osteoarthritis-related serum biochemical markers over 11 years and knee pain in middle-aged adults. (April 2021)

Authors:: Eathakkattu Antony, B.; Singh, A.; Blizzard, L.; Venn, A.; Jones, G.; Burgess, J.; Parameswaran, V.; Ding, C.
Journal:: Osteoarthritis and cartilage
Issue:: Volume 29(2021)Supplement 1
Page Start:: S93
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Cycle stochastic graphs: Structural and forbidden graph characterizations. Issue 3 (1st September 2020)

Authors:: Rao, S. B.; Sahoo, U. K.; Parameswaran, V.
Journal:: AKCE International Journal of Graphs and Combinatorics
Issue:: Volume 17:Issue 3(2020)
Page Start:: 1076
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Long Term Effects Of Vitamin D Supplementation And Maintaining Sufficient Vitamin D On Knee Osteoarthritis Over Five Years. (March 2023)

Authors:: Wang, Z.; Zhu, Z.; Pan, F.; Zheng, S.; Parameswaran, V.; Blizzard, L.; Ding, C.; Antony, B.
Journal:: Osteoarthritis and cartilage
Issue:: Volume 31(2023)Supplement 1
Page Start:: S169
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX). (23rd June 2022)

Authors:: Gupta, V.; Yacoub, A.; Verstovsek, S.; Mesa, R. A.; Harrison, C. N.; Barosi, G.; Kiladjian, J.-J.; Deeg, H. J.; Fazal, S.; Foltz, L.; Mattison, R. J.; Miller, C. B.; Parameswaran, V.; Hernandez, C.; Zhang, J.; Talpaz, M.
Journal:: HemaSphere
Issue:: Volume 6(2022)Supplement 3
Page Start:: 932
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗